Search clinical trials for: Receptor for advanced glycation end products (RAGE)

Total 383972 results

Novo Nordisk A/S

Active, not recruiting

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

Early Alzheimer's Disease

Canada, United States, Spain, Netherlands, United Kingdom, Korea, Republic of, Portugal, Italy, Australia, Argentina, Hungary, Germany, Brazil, Poland, Denmark, Czechia, Ireland, Norway, Japan, Romania, South Africa, Sweden, Mexico, F... and more
Takeda
Takeda Development Center Americas, Inc.

Terminated

A Study of Prucalopride For Functional Constipation in Children and Teenagers

Constipation

United States
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

United States, Korea, Republic of, China, Poland, Taiwan, Turkey, United Kingdom, Australia, Argentina, Germany, Singapore, Thailand, Israel, Russian Federation, Ukraine, Brazil, South Africa
Novo Nordisk A/S

Active, not recruiting

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

Early Alzheimer´s Disease

Canada, United States, Taiwan, Netherlands, United Kingdom, Spain, Austria, Korea, Republic of, Portugal, Italy, Australia, Argentina, Hungary, Germany, Brazil, China, Poland, Denmark, Czechia, Ireland, Japan, South Africa, Romania, S... and more
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Stage IIIA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Breast Adenocarcinoma

United States, Canada
Novo Nordisk A/S

Completed

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (SELECT)

Obesity | Overweight

United States, France, Spain, Taiwan, United Kingdom, Germany, India, Brazil, Canada, Japan, Malaysia, Russian Federation, Australia, Norway, Mexico, Netherlands, Portugal, Hungary, Italy, Austria, Greece, South Africa, Turkey, Finland, Puerto Rico and more
Eli Lilly and Company

Active, not recruiting

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT)

Type 2 Diabetes Mellitus

China, United States, Netherlands, Spain, Australia, Austria, India, Canada, Taiwan, Japan, United Kingdom, Belgium, France, Germany, Mexico, Romania, Italy, Argentina, Brazil, Puerto Rico, Ukraine, Hungary, Czechia, Turkey, Korea, Republic... and more
Bayer

Active, not recruiting

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF)

Heart Failure

United States, Spain, Denmark, Korea, Republic of, Taiwan, Australia, Hong Kong, Russian Federation, Israel, Canada, Malaysia, United Kingdom, Latvia, Netherlands, Japan, Brazil, China, Lithuania, Poland, Turkey, Italy, Austria, Bul... and more
Janssen Research & Development, LLC

Active, not recruiting

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer (PALOMA-3)

Advanced or Metastatic Non-small Cell Lung Cancer

Italy, United States, Germany, Japan, China, Korea, Republic of, Israel, Portugal, Taiwan, Thailand, Malaysia, United Kingdom, Australia, Turkey, Poland, Spain, Brazil, Canada, Argentina, France
CHU de Quebec-Universite Laval
Canadian Institutes of Health Research (CIHR); Biovalorem

Active, not recruiting

Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma

Pancreatic Cancer | Metastatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreas Cancer

Canada
M.D. Anderson Cancer Center

Active, not recruiting

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Malignant Solid Neoplasm | Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Metastatic Melanoma | Stage III Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Unresectable Melanoma | Clinical Stage III Cutaneous... and other conditions

United States
M.D. Anderson Cancer Center

Active, not recruiting

Effects of Mirtazapine on Appetite in Advanced Cancer Patients

Anorexia | Insomnia | Weight Loss | Advanced Cancer

United States
Amgen

Active, not recruiting

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

KRAS p.G12C Mutant Advanced Solid Tumors

United States, France, Canada, Spain, Belgium, Korea, Republic of, Austria, Australia, Hungary, Greece, Germany, Japan, Romania, Switzerland, Brazil, Portugal
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Stage IV Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage IIIB | EGFR Negative Non-Small Cell Lung Cancer

United States
Pfizer

Completed

A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.

Breast Cancer

Denmark
Pfizer
Astellas Pharma Inc; Medivation, Inc.

Active, not recruiting

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Breast Cancer

United States, Spain, Belgium, Canada, Italy, Ireland, United Kingdom
Arbeitsgemeinschaft medikamentoese Tumortherapie
Medical University of Graz; Bionorica SE; Unidata Geodesign

Active, not recruiting

Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer

Chemotherapy-induced Nausea and Vomiting | Pancreatic Cancer Metastatic | Pancreatic Cancer Non-resectable

Austria, Germany
Pfizer
AstraZeneca

Completed

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

Metastatic Breast Cancer

Korea, Republic of, United States, Canada, United Kingdom, Australia, Taiwan, Netherlands, Italy, Japan, Belgium, Ireland, Ukraine, Portugal, Germany, Romania, Russian Federation, Turkey
Pfizer

Completed

Real-world Treatment Patterns of Endocrine Based Therapy Among Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor-2-negative (HR+/HER2-) Advanced Breast Cancer: An Analysis of Administrative Claims Data in Japan

Breast Cancer

Japan
Pfizer

Active, not recruiting

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Neoplasm Metastasis

United States, Spain, Canada, Korea, Republic of, Australia, Japan, Italy, China
Washington University School of Medicine
American Cancer Society, Inc.

Completed

A Low AGE (Advanced Glycation End-product) Dietary Intervention for Breast Cancer Survivors

Breast Cancer

United States
Bayer

Completed

A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer

Solid Tumors Harboring NTRK Fusion

United States, Belgium, Italy, Germany, Australia, Spain, Singapore, Denmark, France, Ireland
QED Therapeutics, Inc.
Helsinn Healthcare SA

Terminated

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF302)

Upper Tract Urothelial Carcinomas | Urothelial Bladder Cancer

United States, France, Canada, Spain, Italy, Belgium, Germany, Netherlands, United Kingdom, Bulgaria, Greece
Immunocore Ltd

Active, not recruiting

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Uveal Melanoma

United States, Canada, United Kingdom, Spain, France, Germany, Poland, Australia, Belgium, Italy, Netherlands, Russian Federation, Switzerland, Ukraine
Theodoros Foukakis

Terminated

HR+/HER2- Advanced Breast Cancer and Endocrine Resistance (PASIPHAE)

Breast Cancer Metastatic

Sweden, United Kingdom
Tianjin Hemay Pharmaceutical Co., Ltd

Completed

Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer

Breast Cancer

China
Instil Bio

Active, not recruiting

ITIL-306 in Advanced Solid Tumors

Renal Cell Carcinoma | Epithelial Ovarian Cancer | Non-small Cell Lung Cancer

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Breast Neoplasms

Korea, Republic of, Germany, United States, United Kingdom, Argentina, Australia, Austria, Brazil, Canada, Chile, China, Colombia, France, Greece, Guatemala, Hungary, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, Phili... and more
Corcept Therapeutics

Completed

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

Adrenocortical Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | HER2-positive Breast Cancer | Advanced Breast Carcinoma | HER2-Positive Breast Carcinoma

United States
Duke University

Active, not recruiting

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

Metastatic Breast Cancer | Locally Advanced Breast Cancer | Hormone Receptor Positive Tumor

United States
Compugen Ltd
Bristol-Myers Squibb

Active, not recruiting

COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

Breast Cancer | Ovarian Cancer | Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Advanced Cancer | Colo-rectal Cancer | Ovarian Neoplasm | Neoplasm Malignant | Lung Neoplasm

United States
Xencor, Inc.
ICON plc

Active, not recruiting

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3)

Renal Cell Carcinoma | Nasopharyngeal Carcinoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Advanced Solid Tumors | Non-small Cell Lung Carcinoma | Squamous Cell Carcinoma of the Head and Neck | Cervical Carcinoma | Endometrial Carcinoma | Urothelial Carcinoma | Colorectal Carcinoma | Pancreatic Carcinoma and other conditions

United States
AstraZeneca

Active, not recruiting

Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. (CONFIRM)

Breast Cancer

Belgium, Spain, Italy, United States, Brazil, Czechia, Russian Federation, Chile, Slovakia, Hungary, India, Ukraine, Venezuela, Colombia, Poland, Malta, Mexico
Olivia Newton-John Cancer Research Institute
Austin Health; Roche Products Pty Limited; Ballarat Health Services

Active, not recruiting

Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy (FLUORO)

Follicular Lymphoma

Australia
UNICANCER
ARCAGY/ GINECO GROUP; SOLTI Breast Cancer Research Group

Active, not recruiting

Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. (DOLAF)

ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer | a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status

France
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

Melanoma

United States, Australia, France, Israel, Italy, Switzerland
Providence Health & Services
Exelixis; Advanced Accelerator Applications SA

Active, not recruiting

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Neuroendocrine Tumors

United States
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Withdrawn

SMMART Adaptive Clinical Treatment (ACT) Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Recurrent... and other conditions

United States
Arvinas Estrogen Receptor, Inc.
Pfizer

Active, not recruiting

ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer (TACTIVE-E)

Breast Cancer

United States, Spain
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IIIC Breast Cancer | HER2/Neu Negative | Stage III Breast Cancer | Postmenopausal | Estrogen Receptor Status

United States
GOG Foundation
Novartis Pharmaceuticals

Active, not recruiting

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

Advanced, Persistent, or Recurrent Endometrial Cancer

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

Melanoma

United States, Australia, France, Israel, Italy, Switzerland
InDex Pharmaceuticals

Terminated

The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis (CONCLUDE)

Ulcerative Colitis

Korea, Republic of, United Kingdom, United States, Mexico, Belgium, Netherlands, Denmark, Poland, Israel, Germany, France, Australia, Austria, Canada, Lithuania, Croatia, Italy, Romania, Turkey, Portugal, Slovakia, Hungary, Norway, Bosnia... and more
Pfizer

Active, not recruiting

A Study of PF-06873600 in People With Cancer

HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer

United States, Japan, Canada, Russian Federation, Bulgaria, Ukraine
Eisai Inc.

Completed

Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer

Breast Cancer | Breast Neoplasms | Cancer, Breast | Breast Cancer Female | Estrogen Receptor Positive Tumor | Breast Adenocarcinoma | ER Positive | Estrogen-receptor Positive Breast Cancer

France, United Kingdom, United States
Mainline Biosciences, Inc.

Withdrawn

A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer

Breast Cancer | Pancreatic Neoplasms | Non Small Cell Lung Cancer | Advanced Solid Tumor | Ovary Cancer
Canadian Cancer Trials Group
Pfizer

Completed

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Breast Cancer

Canada
Fusion Pharmaceuticals Inc.

Terminated

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Breast Cancer | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma | Liver Cancer | Bladder Carcinoma | Susceptible FGFR3 Genetic Alterations | FGFR3 | FGFR3 Overexpression | FGFR3 Receptor | FGFR3 Protein Overexpression

United States, Australia

Search clinical trials for: Receptor for advanced glycation end products (RAGE)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations